FDA Approved: NUCALA — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

FDA approves a supplemental application for NUCALA (mepolizumab) submitted by GlaxoSmithKline LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Eosinophilic Granulomatosis with Polyangiitis

Drugs mentioned

• Nucala (mepolizumab)

Snippet

SUPPL AP for NUCALA (MEPOLIZUMAB)